{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:13:58Z","timestamp":1778523238779,"version":"3.51.4"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00277-023-05459-0","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T23:01:45Z","timestamp":1699743705000},"page":"1493-1511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects"],"prefix":"10.1007","volume":"103","author":[{"given":"Ali Rajabi","family":"Zangi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pouya","family":"Pazooki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Soltanmohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Hamishehkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Javadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"5459_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/JBM.S43734","volume":"4","author":"K Saxena","year":"2013","unstructured":"Saxena K (2013) Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 4:49","journal-title":"J Blood Med"},{"issue":"13","key":"5459_CR2","first-page":"4373","volume":"96","author":"RM Favier","year":"2000","unstructured":"Favier RM, Lavergne J-M, Costa J-M, Caron C, Mazurier C, Vi\u00e9mont Ml et al (2000) Unbalanced X-chromosome inactivation with a novel FVIII gene mutation resulting in severe hemophilia A in a female. Blood J Am Soc Hematol 96(13):4373\u20135","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"5459_CR3","first-page":"17","volume":"1","author":"SK Al-ghtani","year":"2020","unstructured":"Al-ghtani SK (2020) Future of gene therapy in hemophilia. J Univ Stud Incl Res 1(1):17\u201332","journal-title":"J Univ Stud Incl Res"},{"issue":"3","key":"5459_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/ja01207a034","volume":"68","author":"EJ Cohn","year":"1946","unstructured":"Cohn EJ, Strong LE, Hughes W, Mulford D, Ashworth J, Melin ME et al (1946) Preparation and properties of serum and plasma proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a, b, c, d. J Am Chem Soc 68(3):459\u201375","journal-title":"J Am Chem Soc"},{"issue":"6","key":"5459_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/hae.12042","volume":"18","author":"C Kasper","year":"2012","unstructured":"Kasper C (2012) Judith Graham Pool and the discovery of cryoprecipitate. Haemophilia 18(6):833\u2013835","journal-title":"Haemophilia"},{"issue":"6","key":"5459_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/00000441-196512000-00005","volume":"250","author":"WP Webster","year":"1965","unstructured":"Webster WP, Roberts HR, Thelin GM, Wagner RH, Brinkhous KM (1965) Clinical use of a new glycine-precipitated antihemophilic fraction. Am J Med Sci 250(6):643\u2013651","journal-title":"Am J Med Sci"},{"key":"5459_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2016.10.015","volume":"148","author":"K Holstein","year":"2016","unstructured":"Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K et al (2016) Current view and outcome of ITI therapy-a change over time? Thromb Res 148:38\u201344","journal-title":"Thromb Res"},{"key":"5459_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","volume":"20","author":"C-Y Chen","year":"2020","unstructured":"Chen C-Y, Tran DM, Cavedon A, Cai X, Rajendran R, Lyle MJ et al (2020) Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles. Mol Ther-Nucleic Acids 20:534\u2013544","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"10","key":"5459_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/gt.2016.46","volume":"23","author":"F DeRosa","year":"2016","unstructured":"DeRosa F, Guild B, Karve S, Smith L, Love K, Dorkin J et al (2016) Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther 23(10):699\u2013707","journal-title":"Gene Ther"},{"issue":"12","key":"5459_CR10","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1182\/blood-2004-05-2008","volume":"104","author":"I Plug","year":"2004","unstructured":"Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L et al (2004) Thirty years of hemophilia treatment in the Netherlands, 1972\u20132001. Blood 104(12):3494\u20133500","journal-title":"Blood"},{"issue":"1","key":"5459_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF01714977","volume":"62","author":"F Rosendaal","year":"1991","unstructured":"Rosendaal F, Smit C, Briet E (1991) Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol 62(1):5\u201315","journal-title":"Ann Hematol"},{"issue":"23","key":"5459_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"PM Mannucci","year":"2001","unstructured":"Mannucci PM, Tuddenham EG (2001) The hemophilias\u2014from royal genes to gene therapy. N Engl J Med 344(23):1773\u20131779","journal-title":"N Engl J Med"},{"key":"5459_CR13","first-page":"581","volume":"5","author":"R Yatuv","year":"2010","unstructured":"Yatuv R, Robinson M, Dayan-Tarshish I, Baru M (2010) The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int J Nanomed 5:581","journal-title":"Int J Nanomed"},{"issue":"10","key":"5459_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2040620717721458","volume":"8","author":"LA Cafuir","year":"2017","unstructured":"Cafuir LA, Kempton CL (2017) Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hematol 8(10):303\u2013313","journal-title":"Ther Adv Hematol"},{"key":"5459_CR15","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/BF01774523","volume":"68","author":"R Adamson","year":"1994","unstructured":"Adamson R (1994) Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann Haematol 68:S9\u2013S14","journal-title":"Ann Haematol"},{"issue":"5992","key":"5459_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/312342a0","volume":"312","author":"JJ Toole","year":"1984","unstructured":"Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD et al (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312(5992):342\u2013347","journal-title":"Nature"},{"issue":"10","key":"5459_CR17","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1046\/j.1538-7836.2003.00483.x","volume":"1","author":"P Mannucci","year":"2003","unstructured":"Mannucci P (2003) AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J Thromb Haemost 1(10):2065\u20132069","journal-title":"J Thromb Haemost"},{"key":"5459_CR18","doi-asserted-by":"crossref","unstructured":"Franchini M, Mannucci PM, editors (2014) The history of hemophilia. Seminars in thrombosis and hemostasis; Thieme Medical Publishers","DOI":"10.1055\/s-0034-1381232"},{"issue":"5","key":"5459_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1365-2516.2004.00943.x","volume":"10","author":"BM Ewenstein","year":"2004","unstructured":"Ewenstein BM, Valentino L, Journeycake J, Tarantino M, Shapiro A, Blanchette V et al (2004) Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 10(5):629\u201348","journal-title":"Haemophilia"},{"key":"5459_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1365-2516.2009.02156.x","volume":"16","author":"E Santagostino","year":"2010","unstructured":"Santagostino E, Mancuso M (2010) Venous access in haemophilic children: choice and management. Haemophilia 16:20\u201324","journal-title":"Haemophilia"},{"key":"5459_CR21","doi-asserted-by":"crossref","unstructured":"Franchini M, Lippi G, editors (2010) Recombinant factor VIII concentrates. Seminars in thrombosis and hemostasis; \u00a9 Thieme Medical Publishers","DOI":"10.1055\/s-0030-1255443"},{"issue":"4","key":"5459_CR22","first-page":"292","volume":"8","author":"M Franchini","year":"2010","unstructured":"Franchini M (2010) Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 8(4):292","journal-title":"Blood Transfus"},{"key":"5459_CR23","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.2147\/DDDT.S73241","volume":"8","author":"E Santagostino","year":"2014","unstructured":"Santagostino E (2014) A new recombinant factor VIII: from genetics to clinical use. Drug Des Dev Ther 8:2507","journal-title":"Drug Des Dev Ther"},{"issue":"11","key":"5459_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2165\/00003088-200140110-00003","volume":"40","author":"S Bj\u00f6rkman","year":"2001","unstructured":"Bj\u00f6rkman S, Berntorp E (2001) Pharmacokinetics of coagulation factors. Clin Pharmacokinet 40(11):815\u2013832","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"5459_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2004-11-4230","volume":"106","author":"N Bovenschen","year":"2005","unstructured":"Bovenschen N, Mertens K, Hu L, Havekes LM, van Vlijmen BJ (2005) LDL receptor cooperates with LDL receptor\u2013related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 106(3):906\u2013912","journal-title":"Blood"},{"issue":"15","key":"5459_CR26","doi-asserted-by":"publisher","first-page":"11970","DOI":"10.1074\/jbc.M008046200","volume":"276","author":"AG Sarafanov","year":"2001","unstructured":"Sarafanov AG, Ananyeva NM, Shima M, Saenko EL (2001) Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 276(15):11970\u201311979","journal-title":"J Biol Chem"},{"issue":"2","key":"5459_CR27","first-page":"270","volume":"116","author":"B Mei","year":"2010","unstructured":"Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y et al (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood J Am Soc Hematol 116(2):270\u2013279","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"5459_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/17425240802650568","volume":"6","author":"P Bailon","year":"2009","unstructured":"Bailon P, Won C-Y (2009) PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6(1):1\u201316","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"5459_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs 22(5):315\u2013329","journal-title":"BioDrugs"},{"issue":"10","key":"5459_CR30","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1002\/jps.21278","volume":"97","author":"CS Fishburn","year":"2008","unstructured":"Fishburn CS (2008) The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 97(10):4167\u20134183","journal-title":"J Pharm Sci"},{"issue":"1","key":"5459_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s11671-023-03823-7","volume":"18","author":"AR Zangi","year":"2023","unstructured":"Zangi AR, Amiri A, Borzouee F, Bagherifar R, Pazooki P, Hamishehkar H et al (2023) Immobilized nanoparticles-mediated enzyme therapy; promising way into clinical development. Discover Nano 18(1):55","journal-title":"Discover Nano"},{"issue":"2","key":"5459_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2516.2009.02135.x","volume":"16","author":"L Thim","year":"2010","unstructured":"Thim L, Vandahl B, Karlsson J, Klausen N, Pedersen J, Krogh T et al (2010) Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 16(2):349\u2013359","journal-title":"Haemophilia"},{"issue":"6","key":"5459_CR33","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1365-2516.2011.02495.x","volume":"17","author":"U Martinowitz","year":"2011","unstructured":"Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M et al (2011) Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE\u00ae)\u2013an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 17(6):854\u2013859","journal-title":"Haemophilia"},{"issue":"6","key":"5459_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1365-2516.2012.02896.x","volume":"18","author":"H Agers\u00f8","year":"2012","unstructured":"Agers\u00f8 H, Stennicke H, Pelzer H, Olsen E, Merricks E, Defriess N et al (2012) Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia 18(6):941\u2013947","journal-title":"Haemophilia"},{"issue":"4","key":"5459_CR35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jth.12161","volume":"11","author":"A Tiede","year":"2013","unstructured":"Tiede A, Brand B, Fischer R, Kavakli K, Lentz S, Matsushita T et al (2013) Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glyco PEG ylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 11(4):670\u2013678","journal-title":"J Thromb Haemost"},{"key":"5459_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/hae.14056","volume":"27","author":"A Cantore","year":"2021","unstructured":"Cantore A, Naldini L (2021) WFH State-of-the-art paper 2020: In vivo lentiviral vector gene therapy for haemophilia. Haemophilia 27:122\u2013125","journal-title":"Haemophilia"},{"issue":"3","key":"5459_CR37","first-page":"1240","volume":"111","author":"BW Shen","year":"2008","unstructured":"Shen BW, Spiegel PC, Chang C-H, Huh J-W, Lee J-S, Kim J et al (2008) The tertiary structure and domain organization of coagulation factor VIII. Blood J Am Soc Hematol 111(3):1240\u20131247","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"5459_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.str.2008.03.001","volume":"16","author":"JCK Ngo","year":"2008","unstructured":"Ngo JCK, Huang M, Roth DA, Furie BC, Furie B (2008) Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 16(4):597\u2013606","journal-title":"Structure"},{"issue":"5","key":"5459_CR39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1365-2516.2012.02789.x","volume":"18","author":"C Kempton","year":"2012","unstructured":"Kempton C, Abshire T, Deveras R, Hoots W, Gill J, Kessler C et al (2012) Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 18(5):798\u2013804","journal-title":"Haemophilia"},{"issue":"4","key":"5459_CR40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1538-7836.2004.00685.x","volume":"2","author":"E Parker","year":"2004","unstructured":"Parker E, Craddock H, Barrow R, Lollar P (2004) Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate: C in hemophilia A mice presensitized to human factor VIII. J Thromb Haemost 2(4):605\u2013611","journal-title":"J Thromb Haemost"},{"issue":"10","key":"5459_CR41","doi-asserted-by":"publisher","first-page":"e0140740","DOI":"10.1371\/journal.pone.0140740","volume":"10","author":"NA Turner","year":"2015","unstructured":"Turner NA, Moake JL (2015) Factor VIII is synthesized in human endothelial cells, packaged in Weibel-Palade bodies and secreted bound to ULVWF strings. PLoS One 10(10):e0140740","journal-title":"PLoS One"},{"issue":"1","key":"5459_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.thromres.2012.09.011","volume":"131","author":"C Kannicht","year":"2013","unstructured":"Kannicht C, Ramstr\u00f6m M, Kohla G, Tiemeyer M, Casademunt E, Walter O et al (2013) Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 131(1):78\u201388","journal-title":"Thromb Res"},{"issue":"24","key":"5459_CR43","first-page":"3697","volume":"123","author":"LA Everett","year":"2014","unstructured":"Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D (2014) Murine coagulation factor VIII is synthesized in endothelial cells. Blood J Am Soc Hematol 123(24):3697\u20133705","journal-title":"Blood J Am Soc Hematol"},{"key":"5459_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1351-8216.2001.00115.x","volume":"8","author":"R Jiang","year":"2002","unstructured":"Jiang R, Monroe T, McRogers R, Larson P (2002) Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia 8:1\u20135","journal-title":"Haemophilia"},{"issue":"11","key":"5459_CR45","first-page":"3983","volume":"92","author":"PJ Lenting","year":"1998","unstructured":"Lenting PJ, Van Mourik JA, Mertens K (1998) The life cycle of coagulation factor VIII in view of its structure and function. Blood J Am Soc Hematol 92(11):3983\u20133996","journal-title":"Blood J Am Soc Hematol"},{"issue":"8","key":"5459_CR46","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/j.1538-7836.2005.01367.x","volume":"3","author":"SW Pipe","year":"2005","unstructured":"Pipe SW (2005) The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 3(8):1692\u20131701","journal-title":"J Thromb Haemost"},{"issue":"3","key":"5459_CR47","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2003-11-3891","volume":"104","author":"ET Parker","year":"2004","unstructured":"Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P (2004) Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 104(3):704\u2013710","journal-title":"Blood"},{"issue":"5","key":"5459_CR48","first-page":"1594","volume":"95","author":"H Chao","year":"2000","unstructured":"Chao H, Mao L, Bruce AT, Walsh CE (2000) Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood J Am Soc Hematol 95(5):1594\u20131599","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"5459_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1521-2254(200101\/02)3:1<3::AID-JGM167>3.0.CO;2-H","volume":"3","author":"MK Chuah","year":"2001","unstructured":"Chuah MK, Collen D, VandenDriessche T (2001) Gene therapy for hemophilia. J Gene Med 3(1):3\u201320","journal-title":"J Gene Med"},{"issue":"2","key":"5459_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bjh.12091","volume":"160","author":"PW Collins","year":"2013","unstructured":"Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K et al (2013) Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia. Br J Haematol 160(2):153\u2013170","journal-title":"Br J Haematol"},{"issue":"2","key":"5459_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/phar.1173","volume":"33","author":"SR DeFrates","year":"2013","unstructured":"DeFrates SR, McDonagh KT, Adams VR (2013) The reversal of inhibitors in congenital hemophilia. Pharmacother J Human Pharmacol Drug Ther 33(2):157\u201364","journal-title":"Pharmacother J Human Pharmacol Drug Ther"},{"issue":"1","key":"5459_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.12074","volume":"19","author":"M Makris","year":"2013","unstructured":"Makris M, Kasper C (2013) The World Federation of Hemophilia guideline on management of haemophilia. Haemophilia Off J World Fed Hemophilia 19(1):1","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"issue":"10","key":"5459_CR53","first-page":"3663","volume":"89","author":"R Prescott","year":"1997","unstructured":"Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE et al (1997) The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood J Am Soc Hematol 89(10):3663\u20133671","journal-title":"Blood J Am Soc Hematol"},{"issue":"10 Suppl","key":"5459_CR54","first-page":"21","volume":"85","author":"C Hay","year":"2000","unstructured":"Hay C (2000) Porcine factor VIII: past, present and future. Haematologica 85(10 Suppl):21\u20134 (discussion 4)","journal-title":"Haematologica"},{"key":"5459_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1365-2516.2001.00098.x","volume":"7","author":"K High","year":"2001","unstructured":"High K (2001) Gene therapy: a 2001 perspective. Haemophilia 7:23\u201327","journal-title":"Haemophilia"},{"issue":"08","key":"5459_CR56","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1055\/s-0037-1615882","volume":"82","author":"JM Lusher","year":"1999","unstructured":"Lusher JM (1999) Gene therapy for hemophilia A and B: Patient selection and follow-up, requirements for a cure. Thromb Haemost 82(08):572\u2013575","journal-title":"Thromb Haemost"},{"key":"5459_CR57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2516.2000.00055.x","volume":"6","author":"AR Thompson","year":"2000","unstructured":"Thompson AR (2000) Gene therapy for the haemophilias. Haemophilia Off J World Fed Hemophilia 6:115\u20139","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"5459_CR58","unstructured":"High KA, editor Gene transfer as an approach to treating hemophilia. Seminars in thrombosis and hemostasis; 2003: Copyright\u00a9 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New\u00a0\u2026."},{"key":"5459_CR59","unstructured":"Roth D, Tawa N, O'Brien J, Levine J, Furie B, Furie B, et al., editors. Non-viral gene transfer of blood coagulation factor VIII in patients with severe hemophilia A. Blood; 2000: AMER SOC HEMATOLOGY 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA"},{"key":"5459_CR60","unstructured":"Shenk Ti. Adenoviridae: the viruses and their replication, Fields Virology. Fields BN Knipe DM Howley PM. 1996;2111"},{"issue":"1","key":"5459_CR61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham FL, Smiley J, Russell W, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36(1):59\u201372","journal-title":"J Gen Virol"},{"issue":"1","key":"5459_CR62","first-page":"107","volume":"97","author":"AM Gallo-Penn","year":"2001","unstructured":"Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, Cameron C et al (2001) Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood J Am Soc Hematol 97(1):107\u2013113","journal-title":"Blood J Am Soc Hematol"},{"issue":"18","key":"5459_CR63","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1089\/10430349950016401","volume":"10","author":"T Brann","year":"1999","unstructured":"Brann T, Kayda D, Lyons RM, Shirley P, Roy S, Kaleko M et al (1999) Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates. Hum Gene Ther 10(18):2999\u20133011","journal-title":"Hum Gene Ther"},{"issue":"2","key":"5459_CR64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/hum.1996.7.2-183","volume":"7","author":"S Connelly","year":"1996","unstructured":"Connelly S, Gardner JM, McClelland A, Kaleko M (1996) High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 7(2):183\u2013195","journal-title":"Hum Gene Ther"},{"issue":"9","key":"5459_CR65","first-page":"3273","volume":"91","author":"S Connelly","year":"1998","unstructured":"Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L et al (1998) Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood J Am Soc Hematol 91(9):3273\u20133281","journal-title":"Blood J Am Soc Hematol"},{"key":"5459_CR66","doi-asserted-by":"crossref","unstructured":"Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, et al (1996) Complete short-term correction of canine hemophilia A by in vivo gene therapy","DOI":"10.1182\/blood.V88.10.3846.bloodjournal88103846"},{"issue":"5","key":"5459_CR67","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1073\/pnas.92.5.1401","volume":"92","author":"Y Dai","year":"1995","unstructured":"Dai Y, Schwarz EM, Gu D, Zhang W-W, Sarvetnick N, Verma IM (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci 92(5):1401\u20131405","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"5459_CR68","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1073\/pnas.91.10.4407","volume":"91","author":"Y Yang","year":"1994","unstructured":"Yang Y, Nunes FA, Berencsi K, Furth EE, G\u00f6ncz\u00f6l E, Wilson JM (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci 91(10):4407\u20134411","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"5459_CR69","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1128\/jvi.69.4.2004-2015.1995","volume":"69","author":"Y Yang","year":"1995","unstructured":"Yang Y, Li Q, Ertl H, Wilson JM (1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69(4):2004\u20132015","journal-title":"J Virol"},{"issue":"24","key":"5459_CR70","doi-asserted-by":"publisher","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","volume":"93","author":"RJ Parks","year":"1996","unstructured":"Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci 93(24):13565\u201313570","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"5459_CR71","first-page":"820","volume":"95","author":"C Balagu\u00e9","year":"2000","unstructured":"Balagu\u00e9 C, Zhou J, Dai Y, Alemany R, Josephs SF, Andreason G et al (2000) Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood J Am Soc Hematol 95(3):820\u2013828","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"5459_CR72","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/hmg\/5.7.913","volume":"5","author":"R Kumar-Singh","year":"1996","unstructured":"Kumar-Singh R, Chamberlain JS (1996) Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 5(7):913\u2013921","journal-title":"Hum Mol Genet"},{"issue":"2","key":"5459_CR73","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0298-180","volume":"18","author":"G Schiedner","year":"1998","unstructured":"Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C et al (1998) Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 18(2):180\u2013183","journal-title":"Nat Genet"},{"issue":"6","key":"5459_CR74","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1089\/10430340050015473","volume":"11","author":"D Maione","year":"2000","unstructured":"Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, Monica NL et al (2000) Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 11(6):859\u2013868","journal-title":"Hum Gene Ther"},{"issue":"5","key":"5459_CR75","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ymthe.2003.08.014","volume":"8","author":"D Palmer","year":"2003","unstructured":"Palmer D, Ng P (2003) Improved system for helper-dependent adenoviral vector production. Mol Ther 8(5):846\u2013852","journal-title":"Mol Ther"},{"issue":"3","key":"5459_CR76","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2003-05-1426","volume":"103","author":"BD Brown","year":"2004","unstructured":"Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D (2004) Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 103(3):804\u2013810","journal-title":"Blood"},{"issue":"6","key":"5459_CR77","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/j.1538-7836.2006.01901.x","volume":"4","author":"W McCormack Jr","year":"2006","unstructured":"McCormack W Jr, Seiler M, Bertin T, Ubhayakar K, Palmer D, Ng P et al (2006) Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J Thromb Haemost 4(6):1218\u20131225","journal-title":"J Thromb Haemost"},{"issue":"7","key":"5459_CR78","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","volume":"102","author":"A Gringeri","year":"2003","unstructured":"Gringeri A, Mantovani LG, Scalone L, Mannucci PM, Group CS (2003) Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 102(7):2358\u201363","journal-title":"Blood"},{"issue":"5","key":"5459_CR79","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1073\/pnas.1015571108","volume":"108","author":"C Hu","year":"2011","unstructured":"Hu C, Cela RG, Suzuki M, Lee B, Lipshutz GS (2011) Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci 108(5):2082\u20132087","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"5459_CR80","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","volume":"108","author":"H Jiang","year":"2006","unstructured":"Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD et al (2006) Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108(1):107\u2013115","journal-title":"Blood"},{"issue":"26","key":"5459_CR81","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M et al (2017) AAV5\u2013factor VIII gene transfer in severe hemophilia A. N Engl J Med 377(26):2519\u20132530","journal-title":"N Engl J Med"},{"issue":"17","key":"5459_CR82","first-page":"3335","volume":"121","author":"J McIntosh","year":"2013","unstructured":"McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D et al (2013) Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood J Am Soc Hematol 121(17):3335\u20133344","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"5459_CR83","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M et al (2022) Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 386(11):1013\u20131025","journal-title":"N Engl J Med"},{"issue":"21","key":"5459_CR84","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J et al (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371(21):1994\u20132004","journal-title":"N Engl J Med"},{"issue":"1","key":"5459_CR85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B et al (2020) Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med 382(1):29\u201340","journal-title":"N Engl J Med"},{"key":"5459_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.omtm.2018.05.004","volume":"10","author":"A Weber","year":"2018","unstructured":"Weber A, Engelmaier A, Voelkel D, Pachlinger R, Scheiflinger F, Monahan PE et al (2018) Development of methods for the selective measurement of the single amino acid exchange variant coagulation factor IX Padua. Mol Ther-Methods Clin Dev 10:29\u201337","journal-title":"Mol Ther-Methods Clin Dev"},{"issue":"10","key":"5459_CR87","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1634\/stemcells.2006-0699","volume":"25","author":"H Matsui","year":"2007","unstructured":"Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C et al (2007) Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem cells 25(10):2660\u20132669","journal-title":"Stem cells"},{"key":"5459_CR88","doi-asserted-by":"crossref","unstructured":"Gong J, Chung T-H, Zheng J, Zheng H, Chang L-J (2021) Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A. J Biol Chem. 297(6):101397","DOI":"10.1016\/j.jbc.2021.101397"},{"key":"5459_CR89","doi-asserted-by":"publisher","first-page":"15033","DOI":"10.1038\/mtm.2015.33","volume":"2","author":"B Crawford","year":"2015","unstructured":"Crawford B, Ozelo MC, Ogiwara K, Ahlin J, Albanez S, Hegadorn C et al (2015) Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII. Mol Ther-Methods Clin Dev 2:15033","journal-title":"Mol Ther-Methods Clin Dev"},{"issue":"3","key":"5459_CR90","first-page":"798","volume":"117","author":"NJ Ward","year":"2011","unstructured":"Ward NJ, Buckley SM, Waddington SN, VandenDriessche T, Chuah MK, Nathwani AC et al (2011) Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood J Am Soc Hematol 117(3):798\u2013807","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"5459_CR91","first-page":"23","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood J Am Soc Hematol 122(1):23\u201336","journal-title":"Blood J Am Soc Hematol"},{"issue":"24","key":"5459_CR92","first-page":"3184","volume":"129","author":"GL Rogers","year":"2017","unstructured":"Rogers GL, Shirley JL, Zolotukhin I, Kumar SR, Sherman A, Perrin GQ et al (2017) Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells. Blood J Am Soc Hematol 129(24):3184\u20133195","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"5459_CR93","first-page":"526","volume":"114","author":"A Ramezani","year":"2009","unstructured":"Ramezani A, Hawley RG (2009) Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector. Blood J Am Soc Hematol 114(3):526\u2013534","journal-title":"Blood J Am Soc Hematol"},{"key":"5459_CR94","doi-asserted-by":"crossref","unstructured":"Song S, Lyle MJ, Noble-Vranish ML, Min-Tran DM, Harrang J, Xiao W, et al (2022) Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice. Mol Ther-Nucleic Acids","DOI":"10.1016\/j.omtn.2022.01.006"},{"issue":"6","key":"5459_CR95","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1365-2516.2009.02026.x","volume":"15","author":"SW Pipe","year":"2009","unstructured":"Pipe SW (2009) Functional roles of the factor VIII B domain. Haemophilia 15(6):1187\u20131196","journal-title":"Haemophilia"},{"issue":"3","key":"5459_CR96","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cell.2005.07.013","volume":"122","author":"S Ding","year":"2005","unstructured":"Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122(3):473\u2013483","journal-title":"Cell"},{"issue":"1","key":"5459_CR97","first-page":"120","volume":"5","author":"S Zhao","year":"2016","unstructured":"Zhao S, Jiang E, Chen S, Gu Y, Shangguan AJ, Lv T et al (2016) PiggyBac transposon vectors: the tools of the human gene encoding. Transl lung Cancer Res 5(1):120","journal-title":"Transl lung Cancer Res"},{"issue":"8","key":"5459_CR98","doi-asserted-by":"publisher","first-page":"e104957","DOI":"10.1371\/journal.pone.0104957","volume":"9","author":"H Matsui","year":"2014","unstructured":"Matsui H, Fujimoto N, Sasakawa N, Ohinata Y, Shima M, Yamanaka S et al (2014) Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. PLoS One 9(8):e104957","journal-title":"PLoS One"},{"key":"5459_CR99","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.reth.2021.08.009","volume":"18","author":"M Noda","year":"2021","unstructured":"Noda M, Tatsumi K, Matsui H, Matsunari Y, Sato T, Fukuoka Y et al (2021) Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model. Regen Ther 18:347\u2013354","journal-title":"Regen Ther"},{"issue":"7","key":"5459_CR100","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/aor.14512","volume":"47","author":"G Amoabediny","year":"2023","unstructured":"Amoabediny G, Khakbiz M, Jafarkhani S, Mohammadi J, Ilanlou S, Khajouei F et al (2023) The effect of nano-liposomal sodium nitrite on smooth muscle cell growth in a tissue-engineered small-diameter vascular graft. Artif Organs 47(7):1104\u20131121","journal-title":"Artif Organs"},{"issue":"1","key":"5459_CR101","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","volume":"20","author":"SH Kiaie","year":"2022","unstructured":"Kiaie SH, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F et al (2022) Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol 20(1):276","journal-title":"J Nanobiotechnol"},{"key":"5459_CR102","doi-asserted-by":"publisher","first-page":"119269","DOI":"10.1016\/j.ijpharm.2020.119269","volume":"581","author":"SH Kiaie","year":"2020","unstructured":"Kiaie SH, Mojarad-Jabali S, Khaleseh F, Allahyari S, Taheri E, Zakeri-Milani P et al (2020) Axial pharmaceutical properties of liposome in cancer therapy: recent advances and perspectives. Int J Pharm 581:119269","journal-title":"Int J Pharm"},{"issue":"2","key":"5459_CR103","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/138161209787002870","volume":"15","author":"P Debbage","year":"2009","unstructured":"Debbage P (2009) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15(2):153\u2013172","journal-title":"Curr Pharm Des"},{"issue":"10","key":"5459_CR104","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","volume":"55","author":"P Caliceti","year":"2003","unstructured":"Caliceti P, Veronese FM (2003) Pharmacokinetic and biodistribution properties of poly (ethylene glycol)\u2013protein conjugates. Adv Drug Deliv Rev 55(10):1261\u20131277","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"5459_CR105","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0168-3659(03)00201-3","volume":"90","author":"PJ Photos","year":"2003","unstructured":"Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE (2003) Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 90(3):323\u2013334","journal-title":"J Control Release"},{"issue":"12","key":"5459_CR106","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2006-03-008276","volume":"108","author":"J Spira","year":"2006","unstructured":"Spira J, Plyushch OP, Andreeva TA, Andreev Y (2006) Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 108(12):3668\u20133673","journal-title":"Blood"},{"issue":"11","key":"5459_CR107","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1160\/TH12-03-0188","volume":"108","author":"J Powell","year":"2012","unstructured":"Powell J, Martinowitz U, Windyga J, Di Minno G, Hellmann A, Pabinger I et al (2012) Efficacy and safety of prophylaxis with once-weekly BAY 79\u20134980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. Thromb Haemost 108(11):913\u2013922","journal-title":"Thromb Haemost"},{"key":"5459_CR108","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2516.2009.02155.x","volume":"16","author":"G Di Minno","year":"2010","unstructured":"Di Minno G, Cerbone A, Coppola A, Cimino E, Di Capua M, Pamparana F et al (2010) Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue. Haemophilia 16:2\u20136","journal-title":"Haemophilia"},{"issue":"1","key":"5459_CR109","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/nnm.13.192","volume":"9","author":"Q Lin","year":"2014","unstructured":"Lin Q, Chen J, Zhang Z, Zheng G (2014) Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine 9(1):105\u2013120","journal-title":"Nanomedicine"},{"key":"5459_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O et al (2019) Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther-Nucleic Acids 15:1\u201311","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"7","key":"5459_CR111","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.ymthe.2019.04.017","volume":"27","author":"J Cao","year":"2019","unstructured":"Cao J, An D, Galduroz M, Zhuo J, Liang S, Eybye M et al (2019) mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency. Mol Ther 27(7):1242\u20131251","journal-title":"Mol Ther"},{"key":"5459_CR112","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","volume":"156","author":"H Kwon","year":"2018","unstructured":"Kwon H, Kim M, Seo Y, Moon YS, Lee HJ, Lee K et al (2018) Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials 156:172\u2013193","journal-title":"Biomaterials"},{"issue":"11","key":"5459_CR113","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833\u20131840","journal-title":"Mol Ther"},{"key":"5459_CR114","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","volume":"12","author":"S Vaidyanathan","year":"2018","unstructured":"Vaidyanathan S, Azizian KT, Haque AA, Henderson JM, Hendel A, Shore S et al (2018) Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther-Nucleic Acids 12:530\u2013542","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"1","key":"5459_CR115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1566523033347417","volume":"3","author":"EL Saenko","year":"2003","unstructured":"Saenko EL, Ananyeva NM, Moayeri M, Ramezani A, Hawley RG (2003) Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther 3(1):27\u201341","journal-title":"Curr Gene Ther"},{"issue":"2","key":"5459_CR116","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/jps.23963","volume":"104","author":"KA Shetty","year":"2015","unstructured":"Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV (2015) Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci 104(2):388\u2013395","journal-title":"J Pharm Sci"},{"key":"5459_CR117","first-page":"197","volume":"8","author":"S Kiaie","year":"2016","unstructured":"Kiaie S, Karami C, Khodadadian A, Taher M, Soltanian S (2016) A facile method for detection of N-acetylcysteine and l-cysteine with silver nanoparticle in aqueous environments. J Bioequiv Availab 8:197\u2013203","journal-title":"J Bioequiv Availab"},{"key":"5459_CR118","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jiec.2023.04.009","volume":"124","author":"B Tavana","year":"2023","unstructured":"Tavana B, Khatibi A, Jafarkhani S, Zahedi P, Hossein Zamani M, Hassan Jafari S et al (2023) Simulation and in vitro evaluations of microfluidically-fabricated clarithromycin-poly (\u03b5-caprolactone) nanoparticles. J Ind Eng Chem 124:211\u2013223","journal-title":"J Ind Eng Chem"},{"issue":"3","key":"5459_CR119","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0168-3659(00)00361-8","volume":"70","author":"H-Q Mao","year":"2001","unstructured":"Mao H-Q, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y et al (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 70(3):399\u2013421","journal-title":"J Control Release"},{"issue":"3","key":"5459_CR120","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jconrel.2008.06.019","volume":"132","author":"K Bowman","year":"2008","unstructured":"Bowman K, Sarkar R, Raut S, Leong KW (2008) Gene transfer to hemophilia A mice via oral delivery of FVIII\u2013chitosan nanoparticles. J Control Release 132(3):252\u2013259","journal-title":"J Control Release"},{"issue":"9\u201310","key":"5459_CR121","doi-asserted-by":"publisher","first-page":"1449-","DOI":"10.1002\/smll.201370057","volume":"9","author":"D Ling","year":"2013","unstructured":"Ling D, Hyeon T (2013) Iron oxide nanoparticles: chemical design of biocompatible iron oxide nanoparticles for medical applications (Small 9\u201310\/2013). Small 9(9\u201310):1449-","journal-title":"Small"},{"issue":"9\u201310","key":"5459_CR122","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/smll.201202111","volume":"9","author":"D Ling","year":"2013","unstructured":"Ling D, Hyeon T (2013) Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small 9(9\u201310):1450\u20131466","journal-title":"Small"},{"key":"5459_CR123","first-page":"861","volume":"5","author":"J Wang","year":"2010","unstructured":"Wang J, Chen Y, Chen B, Ding J, Xia G, Gao C et al (2010) Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice. Int J Nanomed 5:861","journal-title":"Int J Nanomed"},{"issue":"7","key":"5459_CR124","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1021\/bm070322w","volume":"8","author":"L Cristofolini","year":"2007","unstructured":"Cristofolini L, Berzina T, Erokhina S, Konovalov O, Erokhin V (2007) Structural study of the DNA dipalmitoylphosphatidylcholine complex at the air\u2212 water interface. Biomacromol 8(7):2270\u20132275","journal-title":"Biomacromol"},{"issue":"2","key":"5459_CR125","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","volume":"1329","author":"MC Filion","year":"1997","unstructured":"Filion MC, Phillips NC (1997) Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta (BBA)-Biomembr 1329(2):345\u201356","journal-title":"Biochim Biophys Acta (BBA)-Biomembr"},{"issue":"9","key":"5459_CR126","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3390\/biomedicines9091116","volume":"9","author":"Y-T Kao","year":"2021","unstructured":"Kao Y-T, Chen Y-T, Fan H-C, Tsai T-C, Cheng S-N, Lai P-S et al (2021) Novel coagulation factor viii gene therapy in a mouse model of hemophilia a by lipid-coated fe3o4 nanoparticles. Biomedicines 9(9):1116","journal-title":"Biomedicines"},{"issue":"5","key":"5459_CR127","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2141.2007.06942.x","volume":"140","author":"SL Murphy","year":"2008","unstructured":"Murphy SL, High KA (2008) Gene therapy for haemophilia. Br J Haematol 140(5):479\u2013487","journal-title":"Br J Haematol"},{"issue":"4","key":"5459_CR128","first-page":"1133","volume":"100","author":"BD Brown","year":"2002","unstructured":"Brown BD, Lillicrap D (2002) Dangerous liaisons: the role of \u201cdanger\u201d signals in the immune response to gene therapy. Blood J Am Soc Hematol 100(4):1133\u20131140","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"5459_CR129","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21(6):704\u2013712","journal-title":"Hum Gene Ther"},{"key":"5459_CR130","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1111\/jth.12926","volume":"13","author":"T Ohmori","year":"2015","unstructured":"Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S (2015) New approaches to gene and cell therapy for hemophilia. J Thromb Haemost 13:S133\u2013S142","journal-title":"J Thromb Haemost"},{"issue":"23","key":"5459_CR131","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","volume":"344","author":"DA Roth","year":"2001","unstructured":"Roth DA, Tawa NE Jr, O\u2019Brien JM, Treco DA, Selden RF (2001) Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 344(23):1735\u20131742","journal-title":"N Engl J Med"},{"issue":"03","key":"5459_CR132","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1055\/s-0038-1648444","volume":"67","author":"R Hoeben","year":"1992","unstructured":"Hoeben R, Einerhand M, Briet E, Van Ormondt H, Valerio D, Van Der Eb A (1992) Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 67(03):341\u2013345","journal-title":"Thromb Haemost"},{"issue":"5","key":"5459_CR133","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ymthe.2004.08.006","volume":"10","author":"M Moayeri","year":"2004","unstructured":"Moayeri M, Ramezani A, Morgan RA, Hawley TS, Hawley RG (2004) Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 10(5):892\u2013902","journal-title":"Mol Ther"},{"issue":"12","key":"5459_CR134","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jgg.2013.11.002","volume":"40","author":"Q Wang","year":"2013","unstructured":"Wang Q, Gong X, Gong Z, Ren X, Ren Z, Huang S et al (2013) The mesenchymal stem cells derived from transgenic mice carrying human coagulation factor VIII can correct phenotype in hemophilia A mice. J Genet Genomics 40(12):617\u2013628","journal-title":"J Genet Genomics"},{"issue":"25","key":"5459_CR135","doi-asserted-by":"publisher","first-page":"9253","DOI":"10.1073\/pnas.1323941111","volume":"111","author":"C-Y Park","year":"2014","unstructured":"Park C-Y, Kim J, Kweon J, Son JS, Lee JS, Yoo J-E et al (2014) Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc Natl Acad Sci 111(25):9253\u20139258","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"5459_CR136","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4238\/2013.May.13.4","volume":"12","author":"J Wang","year":"2013","unstructured":"Wang J, Kuang Y, Zhang L, Shen C, Wang L, Lu S et al (2013) Phenotypic correction and stable expression of factor VIII in hemophilia A mice by embryonic stem cell therapy. Genet Mol Res 12(2):1511\u20131521","journal-title":"Genet Mol Res"},{"key":"5459_CR137","unstructured":"Cucci A, Olgasi C, Merlin S, Borsotti C, Bergmann T, Bittorf P, et al (2020) Combined gene and cell therapy for the treatment of hemophilia A within an implantable therapeutic device"},{"issue":"10","key":"5459_CR138","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1073\/pnas.95.10.5734","volume":"95","author":"GL Evans","year":"1998","unstructured":"Evans GL, Morgan RA (1998) Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci 95(10):5734\u20135739","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"5459_CR139","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.4049\/jimmunol.155.11.5404","volume":"155","author":"BA Ally","year":"1995","unstructured":"Ally BA, Hawley TS, McKall-Faienza KJ, K\u00fcndig T, Oehen SU, Pircher H et al (1995) Prevention of autoimmune disease by retroviral-mediated gene therapy. J Immunol 155(11):5404\u20135408","journal-title":"J Immunol"},{"issue":"2","key":"5459_CR140","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ymthe.2005.03.035","volume":"12","author":"D Forman","year":"2005","unstructured":"Forman D, Tian C, Iacomini J (2005) Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy. Mol Ther 12(2):353\u2013359","journal-title":"Mol Ther"},{"issue":"12","key":"5459_CR141","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.4049\/jimmunol.173.12.7217","volume":"173","author":"C Tian","year":"2004","unstructured":"Tian C, Bagley J, Forman D, Iacomini J (2004) Induction of central tolerance by mature T cells. J Immunol 173(12):7217\u20137222","journal-title":"J Immunol"},{"issue":"6","key":"5459_CR142","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ymthe.2005.09.007","volume":"12","author":"M Moayeri","year":"2005","unstructured":"Moayeri M, Hawley TS, Hawley RG (2005) Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther 12(6):1034\u20131042","journal-title":"Mol Ther"},{"issue":"5","key":"5459_CR143","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bjh.17580","volume":"194","author":"H Fassel","year":"2021","unstructured":"Fassel H, McGuinn C (2021) Haemophilia: factoring in new therapies. Br J Haematol 194(5):835\u2013850","journal-title":"Br J Haematol"},{"issue":"11","key":"5459_CR144","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41551-018-0275-1","volume":"2","author":"MA Bochenek","year":"2018","unstructured":"Bochenek MA, Veiseh O, Vegas AJ, McGarrigle JJ, Qi M, Marchese E et al (2018) Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat Biomed Eng 2(11):810\u2013821","journal-title":"Nat Biomed Eng"},{"key":"5459_CR145","unstructured":"Barney L, Heidebrecht Jr RW, Carmona G, Sewell J, Oberli M, Huang J, et al., editors. Optimization of shielded encapsulated cell therapy for hemophilia and beyond. Molecular Therapy; 2020: CELL PRESS 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA"},{"key":"5459_CR146","first-page":"8","volume":"136","author":"AD Shapiro","year":"2020","unstructured":"Shapiro AD, Konkle BA, Croteau SE, Miesbach WA, Hay CRM, Kazmi R et al (2020) First-in-human phase 1\/2 clinical trial of SIG-001, an innovative shielded cell therapy platform, for hemophilia \u0391. Blood 136:8","journal-title":"Blood"},{"key":"5459_CR147","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.trsl.2017.06.002","volume":"187","author":"K Parvathaneni","year":"2017","unstructured":"Parvathaneni K, Abdeladhim M, Pratt KP, Scott DW (2017) Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy. Transl Res 187:44\u201352","journal-title":"Transl Res"},{"key":"5459_CR148","doi-asserted-by":"publisher","first-page":"14030","DOI":"10.1038\/mtm.2014.30","volume":"1","author":"D Sarkar","year":"2014","unstructured":"Sarkar D, Biswas M, Liao G, Seay HR, Perrin GQ, Markusic DM et al (2014) Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia. Mol Ther-Methods Clin Dev 1:14030","journal-title":"Mol Ther-Methods Clin Dev"},{"issue":"2","key":"5459_CR149","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/jth.14659","volume":"18","author":"BM Smith","year":"2020","unstructured":"Smith BM, Lyle MJ, Chen AC, Miao CH (2020) Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice. J Thromb Haemost 18(2):328\u2013340","journal-title":"J Thromb Haemost"},{"issue":"2","key":"5459_CR150","doi-asserted-by":"publisher","first-page":"858","DOI":"10.4049\/jimmunol.180.2.858","volume":"180","author":"J-G Chai","year":"2008","unstructured":"Chai J-G, Coe D, Chen D, Simpson E, Dyson J, Scott D (2008) In vitro expansion improves in vivo regulation by CD4+ CD25+ regulatory T cells. J Immunol 180(2):858\u2013869","journal-title":"J Immunol"},{"issue":"6","key":"5459_CR151","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/art.30328","volume":"63","author":"G Ojeda","year":"2011","unstructured":"Ojeda G, Pini E, Eguiluz C, Montes-Casado M, Broere F, van Eden W et al (2011) Complement regulatory protein Crry\/p65 costimulation expands natural treg cells with enhanced suppressive properties in proteoglycan-induced arthritis. Arthritis Rheum 63(6):1562\u20131572","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5459_CR152","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T et al (2012) A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18(10):1570\u20131574","journal-title":"Nat Med"},{"issue":"11","key":"5459_CR153","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12(11):967\u2013977","journal-title":"Nat Mater"},{"issue":"9","key":"5459_CR154","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s12272-018-1069-4","volume":"41","author":"K Lee","year":"2018","unstructured":"Lee K, Jang B, Lee Y-R, Suh E-Y, Yoo J-S, Lee M-J et al (2018) The cutting-edge technologies of siRNA delivery and their application in clinical trials. Arch Pharm Res 41(9):867\u201374","journal-title":"Arch Pharm Res"},{"issue":"4","key":"5459_CR155","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/ehm.10.33","volume":"3","author":"CH Miao","year":"2010","unstructured":"Miao CH (2010) Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 3(4):469\u2013483","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"5459_CR156","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.15270","volume":"19","author":"KJ Pasi","year":"2021","unstructured":"Pasi KJ, Lissitchkov T, Mamonov V, Mant T, Timofeeva M, Bagot C et al (2021) Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran\u2014results of the phase 1 inhibitor cohort. J Thromb Haemost 19(6):1436\u20131446","journal-title":"J Thromb Haemost"},{"key":"5459_CR157","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1182\/blood-2021-147286","volume":"138","author":"V Cano","year":"2021","unstructured":"Cano V, Bartelt-Hofer J, Hu W, Andersson SR, Dasmahapatra P, Von Mackensen S (2021) Sustained improvement in health-related quality of life in patients with hemophilia A with or without inhibitors treated with fitusiran prophylaxis. Blood 138:3197","journal-title":"Blood"},{"issue":"2","key":"5459_CR158","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.stem.2015.07.001","volume":"17","author":"C-Y Park","year":"2015","unstructured":"Park C-Y, Kim DH, Son JS, Sung JJ, Lee J, Bae S et al (2015) Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell 17(2):213\u2013220","journal-title":"Cell Stem Cell"},{"key":"5459_CR159","doi-asserted-by":"publisher","first-page":"121429","DOI":"10.1016\/j.biomaterials.2022.121429","volume":"283","author":"JS Son","year":"2022","unstructured":"Son JS, Park C-Y, Lee G, Park JY, Kim HJ, Kim G et al (2022) Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR\/Cas9-engineered patient iPSCs. Biomaterials 283:121429","journal-title":"Biomaterials"},{"issue":"4","key":"5459_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0243-1","volume":"51","author":"JJ Sung","year":"2019","unstructured":"Sung JJ, Park C-Y, Leem JW, Cho MS, Kim D-W (2019) Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs. Exp Mol Med 51(4):1\u20139","journal-title":"Exp Mol Med"},{"issue":"2","key":"5459_CR161","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1042\/BA20010082","volume":"35","author":"HS Kingdon","year":"2002","unstructured":"Kingdon HS, Lundblad RL (2002) An adventure in biotechnology: the development of haemophilia A therapeutics\u2013from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem 35(2):141\u2013148","journal-title":"Biotechnol Appl Biochem"},{"issue":"6","key":"5459_CR162","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2516.2006.01338.x","volume":"12","author":"K Peerlinck","year":"2006","unstructured":"Peerlinck K, Hermans C (2006) Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 12(6):579\u2013590","journal-title":"Haemophilia"},{"key":"5459_CR163","unstructured":"Factor A, Factor C, Tarrytown N (2010) HELIXATE\u00ae FS. Director 267:685\u20132781\u00a0"},{"issue":"2","key":"5459_CR164","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2516.2006.01416.x","volume":"13","author":"H Pollmann","year":"2007","unstructured":"Pollmann H, Externest D, Ganser A, Eifrig B, Kreuz W, Lenk H et al (2007) Efficacy, safety and tolerability of recombinant factor VIII (REFACTO\u00ae) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 13(2):131\u2013143","journal-title":"Haemophilia"},{"issue":"1","key":"5459_CR165","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1046\/j.1365-2516.2003.00708.x","volume":"9","author":"J Lusher","year":"2003","unstructured":"Lusher J, Lee C, Kessler C, Bedrosian C, Group RPS (2003) The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9(1):38\u201349","journal-title":"Haemophilia"},{"issue":"5","key":"5459_CR166","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/hae.12985","volume":"22","author":"R Klamroth","year":"2016","unstructured":"Klamroth R, Simpson M, von Depka-Prondzinski M, Gill J, Morfini M, Powell JS et al (2016) Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate\u00ae) in patients with severe haemophilia A. Haemophilia 22(5):730\u2013738","journal-title":"Haemophilia"},{"issue":"5","key":"5459_CR167","first-page":"555","volume":"3","author":"AD Shapiro","year":"2007","unstructured":"Shapiro AD (2007) Anti-hemophilic factor (recombinant), plasma\/albumin-free method (octocog-alpha; ADVATE\u00ae) in the management of hemophilia A. Vasc Health Risk Manag 3(5):555","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"5459_CR168","first-page":"630","volume":"128","author":"J Mahlangu","year":"2016","unstructured":"Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM et al (2016) Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia A. Blood J Am Soc Hematol 128(5):630\u2013637","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"5459_CR169","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.thromres.2013.06.017","volume":"132","author":"SB Zollner","year":"2013","unstructured":"Zollner SB, Raquet E, M\u00fcller-Cohrs J, Metzner HJ, Weimer T, Pragst I et al (2013) Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res 132(2):280\u2013287","journal-title":"Thromb Res"},{"issue":"1","key":"5459_CR170","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/hae.12518","volume":"21","author":"E Santagostino","year":"2015","unstructured":"Santagostino E, Lentz S, Misgav M, Brand B, Chowdary P, Savic A et al (2015) Safety and efficacy of turoctocog alfa (NovoEight\u00ae) during surgery in patients with haemophilia A: results from the multinational guardian\u2122 clinical trials. Haemophilia 21(1):34\u201340","journal-title":"Haemophilia"},{"issue":"3","key":"5459_CR171","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/jth.12816","volume":"13","author":"V Jim\u00e9nez-Yuste","year":"2015","unstructured":"Jim\u00e9nez-Yuste V, Lejniece S, Klamroth R, Suzuki T, Santagostino E, Karim F et al (2015) The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight\u00ae), in patients with hemophilia A. J Thromb Haemost 13(3):370\u2013379","journal-title":"J Thromb Haemost"},{"key":"5459_CR172","doi-asserted-by":"publisher","first-page":"204062071985847","DOI":"10.1177\/2040620719858471","volume":"10","author":"T Lissitchkov","year":"2019","unstructured":"Lissitchkov T, Klukowska A, Pasi J, Kessler CM, Klamroth R, Liesner RJ et al (2019) Efficacy and safety of simoctocog alfa (Nuwiq\u00ae) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Ther Adv Hematol 10:2040620719858471","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"5459_CR173","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40259-016-0191-4","volume":"30","author":"GM Keating","year":"2016","unstructured":"Keating GM (2016) BAY 81\u20138973 (Octocog Alfa; Kovaltry\u00ae): A Review in Haemophilia A. BioDrugs 30(5):453\u2013459","journal-title":"BioDrugs"},{"key":"5459_CR174","unstructured":"D\u2019Angiolella LS, Molinari AC, Cortesi PA, Coppola A, Mantovani LG (2017) Kovaltry\u00ae nel trattamento dell\u2019emofilia A: aspetti clinici ed economici nei trial clinici registrativi"},{"issue":"23","key":"5459_CR175","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, Rasko JE, Samelson-Jones BJ, Ducore J et al (2017) Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 377(23):2215\u20132227","journal-title":"N Engl J Med"},{"issue":"11","key":"5459_CR176","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1089\/hum.2017.150","volume":"28","author":"C Vandamme","year":"2017","unstructured":"Vandamme C, Adjali O, Mingozzi F (2017) Unraveling the complex story of immune responses to AAV vectors trial after trial. Hum Gene Ther 28(11):1061\u20131074","journal-title":"Hum Gene Ther"},{"issue":"9","key":"5459_CR177","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1517\/21678707.2015.1069179","volume":"3","author":"VR Arruda","year":"2015","unstructured":"Arruda VR, Samelson-Jones BJ (2015) Obstacles and future of gene therapy for hemophilia. Expert Opin Orphan Drugs 3(9):997\u20131010","journal-title":"Expert Opin Orphan Drugs"},{"issue":"21","key":"5459_CR178","first-page":"4396","volume":"121","author":"JI Siner","year":"2013","unstructured":"Siner JI, Iacobelli NP, Sabatino DE, Ivanciu L, Zhou S, Poncz M et al (2013) Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood J Am Soc Hematol 121(21):4396\u20134403","journal-title":"Blood J Am Soc Hematol"},{"issue":"7573","key":"5459_CR179","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini L (2015) Gene therapy returns to centre stage. Nature 526(7573):351\u2013360","journal-title":"Nature"},{"issue":"3","key":"5459_CR180","doi-asserted-by":"publisher","first-page":"e9958","DOI":"10.15252\/emmm.201809958","volume":"11","author":"L Naldini","year":"2019","unstructured":"Naldini L (2019) Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. EMBO Mol Med 11(3):e9958","journal-title":"EMBO Mol Med"},{"issue":"10","key":"5459_CR181","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1089\/hum.2018.137","volume":"29","author":"CB Doering","year":"2018","unstructured":"Doering CB, Denning G, Shields JE, Fine EJ, Parker ET, Srivastava A et al (2018) Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A. Hum Gene Ther 29(10):1183\u20131201","journal-title":"Hum Gene Ther"},{"key":"5459_CR182","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0958-1669(98)80031-1","volume":"9","author":"K Berns","year":"1998","unstructured":"Berns K, Bohenzky R (1998) Adeno-associated virus expression system for gene transfer. Curr Opin Biotechnol 9:470\u2013475","journal-title":"Curr Opin Biotechnol"},{"issue":"17","key":"5459_CR183","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","volume":"7","author":"J-Y Dong","year":"1996","unstructured":"Dong J-Y, Fan P-D, Frizzell RA (1996) Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7(17):2101\u20132112","journal-title":"Hum Gene Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05459-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05459-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05459-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:03:24Z","timestamp":1712901804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05459-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":183,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5459"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05459-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}